Eisai announces the expansion of its operations in South Africa with the registration of two products (Halaven® (eribulin) for metastatic breast cancer and Fycompa® (perampanel) …
Eisai announces the expansion of its operations in South Africa with the registration of two products (Halaven® (eribulin) for metastatic breast cancer and Fycompa® (perampanel) …